Luoxin Pharmaceuticals Group Stock Co Ltd (002793) - Net Assets
Based on the latest financial reports, Luoxin Pharmaceuticals Group Stock Co Ltd (002793) has net assets worth CN¥1.53 Billion CNY (≈ $223.90 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.99 Billion ≈ $583.88 Million USD) and total liabilities (CN¥2.46 Billion ≈ $359.98 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Luoxin Pharmaceuticals Group Stock Co Lt (002793) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.53 Billion |
| % of Total Assets | 38.35% |
| Annual Growth Rate | 19.01% |
| 5-Year Change | -66.45% |
| 10-Year Change | 329.87% |
| Growth Volatility | 92.85 |
Luoxin Pharmaceuticals Group Stock Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Luoxin Pharmaceuticals Group Stock Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 002793 asset base for the complete picture of this company's asset base.
Annual Net Assets for Luoxin Pharmaceuticals Group Stock Co Ltd (2011–2024)
The table below shows the annual net assets of Luoxin Pharmaceuticals Group Stock Co Ltd from 2011 to 2024. For live valuation and market cap data, see 002793 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.46 Billion ≈ $213.56 Million |
-43.27% |
| 2023-12-31 | CN¥2.57 Billion ≈ $376.42 Million |
-22.20% |
| 2022-12-31 | CN¥3.31 Billion ≈ $483.84 Million |
-30.18% |
| 2021-12-31 | CN¥4.74 Billion ≈ $692.99 Million |
+8.86% |
| 2020-12-31 | CN¥4.35 Billion ≈ $636.59 Million |
+9.81% |
| 2019-12-31 | CN¥3.96 Billion ≈ $579.73 Million |
+335.41% |
| 2018-12-31 | CN¥909.89 Million ≈ $133.14 Million |
+20.64% |
| 2017-12-31 | CN¥754.19 Million ≈ $110.36 Million |
+8.00% |
| 2016-12-31 | CN¥698.33 Million ≈ $102.19 Million |
+105.70% |
| 2015-12-31 | CN¥339.50 Million ≈ $49.68 Million |
+7.62% |
| 2014-12-31 | CN¥315.46 Million ≈ $46.16 Million |
+25.43% |
| 2013-12-31 | CN¥251.50 Million ≈ $36.80 Million |
+22.36% |
| 2012-12-31 | CN¥205.54 Million ≈ $30.08 Million |
+35.34% |
| 2011-12-31 | CN¥151.87 Million ≈ $22.22 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Luoxin Pharmaceuticals Group Stock Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 242.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥1.09 Billion | 78.68% |
| Other Comprehensive Income | CN¥43.92 Million | 3.18% |
| Other Components | CN¥341.05 Million | 24.67% |
| Total Equity | CN¥1.38 Billion | 100.00% |
Luoxin Pharmaceuticals Group Stock Co Ltd Competitors by Market Cap
The table below lists competitors of Luoxin Pharmaceuticals Group Stock Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PARATUS ENERGY SERVICES LTD
OL:PLSV
|
$880.19 Million |
|
Baotailong New Materials Co Ltd
SHG:601011
|
$880.21 Million |
|
Stevanato Group SpA
NYSE:STVN
|
$880.36 Million |
|
United Overseas Australia Ltd
AU:UOS
|
$880.66 Million |
|
BlackRock Health Sciences Trust II
NYSE:BMEZ
|
$880.02 Million |
|
Orezone Gold Corporation
AU:ORE
|
$879.80 Million |
|
Nanjing Quanxin Cable Technology Co Ltd
SHE:300447
|
$879.74 Million |
|
Citic Guoan Wine Co Ltd
SHG:600084
|
$879.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Luoxin Pharmaceuticals Group Stock Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,469,901,453 to 1,382,277,279, a change of -1,087,624,174 (-44.0%).
- Net loss of 965,496,155 reduced equity.
- Dividend payments of 61,191,581 reduced retained earnings.
- Share repurchases of 99,998,598 reduced equity.
- Other comprehensive income increased equity by 3,244,237.
- Other factors increased equity by 35,817,923.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-965.50 Million | -69.85% |
| Dividends Paid | CN¥61.19 Million | -4.43% |
| Share Repurchases | CN¥100.00 Million | -7.23% |
| Other Comprehensive Income | CN¥3.24 Million | +0.23% |
| Other Changes | CN¥35.82 Million | +2.59% |
| Total Change | CN¥- | -44.04% |
Book Value vs Market Value Analysis
This analysis compares Luoxin Pharmaceuticals Group Stock Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.24x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 22.20x to 4.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.25 | CN¥5.53 | x |
| 2012-12-31 | CN¥0.34 | CN¥5.53 | x |
| 2013-12-31 | CN¥0.41 | CN¥5.53 | x |
| 2014-12-31 | CN¥0.52 | CN¥5.53 | x |
| 2015-12-31 | CN¥0.56 | CN¥5.53 | x |
| 2016-12-31 | CN¥1.15 | CN¥5.53 | x |
| 2017-12-31 | CN¥2.22 | CN¥5.53 | x |
| 2018-12-31 | CN¥0.85 | CN¥5.53 | x |
| 2019-12-31 | CN¥3.31 | CN¥5.53 | x |
| 2020-12-31 | CN¥2.77 | CN¥5.53 | x |
| 2021-12-31 | CN¥3.02 | CN¥5.53 | x |
| 2022-12-31 | CN¥2.23 | CN¥5.53 | x |
| 2023-12-31 | CN¥2.28 | CN¥5.53 | x |
| 2024-12-31 | CN¥1.30 | CN¥5.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Luoxin Pharmaceuticals Group Stock Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -69.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -36.47%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 3.14x
- Recent ROE (-69.85%) is below the historical average (51.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 21.41% | 7.68% | 1.56x | 1.79x | CN¥17.33 Million |
| 2012 | 214.01% | 19.74% | 5.98x | 1.81x | CN¥419.32 Million |
| 2013 | 170.41% | 16.94% | 6.96x | 1.44x | CN¥403.44 Million |
| 2014 | 140.61% | 16.03% | 6.18x | 1.42x | CN¥412.01 Million |
| 2015 | 145.19% | 13.65% | 6.57x | 1.62x | CN¥458.98 Million |
| 2016 | 54.30% | 9.21% | 5.07x | 1.16x | CN¥309.36 Million |
| 2017 | 15.36% | 13.99% | 0.92x | 1.19x | CN¥40.43 Million |
| 2018 | 56.31% | 8.25% | 4.43x | 1.54x | CN¥421.33 Million |
| 2019 | 17.23% | 8.35% | 1.02x | 2.03x | CN¥266.04 Million |
| 2020 | 7.94% | 5.26% | 0.79x | 1.91x | CN¥-83.35 Million |
| 2021 | 9.26% | 6.27% | 0.68x | 2.17x | CN¥-32.36 Million |
| 2022 | -38.59% | -34.14% | 0.44x | 2.55x | CN¥-1.54 Billion |
| 2023 | -26.77% | -27.97% | 0.46x | 2.07x | CN¥-908.13 Million |
| 2024 | -69.85% | -36.47% | 0.61x | 3.14x | CN¥-1.10 Billion |
Industry Comparison
This section compares Luoxin Pharmaceuticals Group Stock Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Luoxin Pharmaceuticals Group Stock Co Ltd (002793) | CN¥1.53 Billion | 21.41% | 1.61x | $880.09 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Luoxin Pharmaceuticals Group Stock Co Ltd
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, manufacture, and trading of drugs in China. The company provides antiviral, anti-infective, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates. … Read more